CHRONIC LYMPHOCYTIC LEUKEMIA

慢性淋巴细胞白血病

• 批准号: 7604967
• 负责人: MARGARET K-H YU
• 金额: $ 3.39万
• 依托单位: UNIVERSITY OF UTAH
• 依托单位国家: 美国
• 财政年份: 2007
• 资助国家: 美国
• 起止时间: 2007-03-01 至 2008-02-29
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7604967
• 关键词: Chronic Lymphocytic Leukemia; Computer Retrieval of Information on Scientific Projects Database; DNA Methylation; Disease; Dysmyelopoietic Syndromes; Funding; Grant; Institution; Malignant Neoplasms; Patients; Research; Research Personnel; Resources; Source; Tumor Suppressor Genes; United States National Institutes of Health; Vidaza; inhibitor/antagonist; novel

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Chronic lymphocytic leukemia is rarely curative disease. Novel treatments are needed. Like many other malignancies, tumor suppressor genes may be silenced by DNA methylation in chronic lymphocytic leukemia. Vidaza, a DNA methylation inhibitor, is already approved for treatment of patients with myelodysplastic syndrome. This study proposes to study if Vidaza is an effective DNA methylation inhibitor in patients with chronic lymphocytic leukemia.

这个子项目是许多研究子项目中的一个 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者（PI）可能从另一个NIH来源获得了主要资金， 因此可以在其他CRISP条目中表示。所列机构为 研究中心，而研究中心不一定是研究者所在的机构。 慢性淋巴细胞白血病是一种罕见的可治愈疾病。需要新的治疗方法。与许多其他恶性肿瘤一样，慢性淋巴细胞白血病中的肿瘤抑制基因可能因DNA甲基化而沉默。DNA甲基化抑制剂Vidaza已经被批准用于治疗骨髓增生异常综合征患者。本研究旨在研究维达扎是否是慢性淋巴细胞白血病患者有效的DNA甲基化抑制剂。